ECCO Abstract Awards at the 12th Congress of ECCO
Top 10 Digital Oral Presentations

• “Ethnicity and country of birth are associated with phenotypic differences in patients with Inflammatory Bowel Disease” (DOP004), L.M. Spekhorst et al, University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands

• “Transmural healing is better than mucosal healing in Crohn's Disease” (DOP014), S. Raimundo Fernandes et al, Hospital de Santa Maria, Serviço de Gastroenterologia e Hepatologia, Lisboa, Portugal

• “Efficacy of vedolizumab on extraintestinal manifestation in patients with Inflammatory Bowel Disease: A post-hoc analysis of the OBSERV-IBD cohort from the GETAID” (DOP025), A. Amiot et al, Henri Mondor Hospital, Gastroenterology, Creteil, France

• “High gammaglobulin and low albumin serum levels independently predict secondary loss of response to anti-TNFα therapy in IBD” (DOP035), F. Schoenefuss et al, Kliniken Essen Mitte, Gastroenterology, Essen, Germany

• “Relationship between microbiota and development of early postoperative Crohn’s Disease recurrence” (DOP044), K. Machiels et al, University Hospitals Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium

• “PROFILE trial: Predicting outcomes for Crohn’s Disease using a molecular biomarker” (DOP048), N. Noor et al, University of Cambridge, School of Clinical Medicine; Addenbrooke’s Hospital NHS Trust, Department of Gastroenterology, Cambridge, United Kingdom

• “New human gut xenograft mouse model for intestinal fistulas” (DOP059), R. S. Bruckner et al, University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

• “Use of chromoendoscopy versus white light endoscopy for colorectal cancer surveillance in Inflammatory Bowel Disease patients with primary sclerosing cholangitis; a six year experience” (DOP065), K. Hartery et al, John Radcliffe Hospital, Translation Gastroenterology Unit, Oxford, United Kingdom
*Submucosal injection of the oligonucleotide STNM01 is able to induce clinical remission, mucosal healing and histological response in left-sided Ulcerative Colitis patients with moderate-to-severe disease* (DOP073), R. Atreya et al, Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany

*Tight NADPH oxidase regulation is a prerequisite for gut health* (DOP085), G. Aviello et al, National Children's Research Centre, Our Lady's Children's Hospital, Dublin, Ireland

**Y-ECCO Abstract Awards**

*Whole genome sequencing and imputation in Inflammatory Bowel Disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights* (OP001), L. Moutsianas et al, Wellcome Trust Sanger Institute, Human Genetics, Hinxton, Cambridge, United Kingdom

*Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial* (OP006), L. Pouillon et al, University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium

*Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach* (OP017), M.J. de Jong et al, Maastricht University Medical Center (MUMC), Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands

*Optimal anti-TNF stop week during pregnancy depends on anti-TNF type* (OP018), S.L. Kanis et al, Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands

*IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer* (OP027), L. R. Lopetuso et al., Catholic University of the Sacred Hearth, Internal Medicine, Gastroenterology Division, Rome, Italy

**IIS Abstract Awards**

*Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active Ulcerative Colitis: A randomised controlled trial* (OP036), S. Costello et al, The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia

*Long-term safety of in utero exposure to anti-tumor necrosis factor for the treatment of Inflammatory Bowel Diseases: Results from the multicenter European TEDDY study* (DOP016) M. Chaparro, Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Madrid, Spain

**Congratulations!**